Drug Trial Radar · NCT07053423
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
Sep 22, 2025
Primary completion
Dec 23, 2028
Study completion Feb 2, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive). Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The number of visits will be 9.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
DupilumabDrug
Pharmaceutical form:Solution for injection-Route of administration:SC injection
PlaceboDrug
Pharmaceutical form:Solution for injection-Route of administration:SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to Week 24 in global lung mucus score (UCSF mucus scoring)Time frame: Baseline to Week 24
Locations
85 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - School of Medicine- Site Number : 8400003
Birmingham, Alabama · Recruiting
University of Miami Dermatology Clinical Trials Unit- Site Number : 8400015
Miami, Florida · Recruiting
Finlay Medical Research- Site Number : 8400010
Miami, Florida · Recruiting
Private Practice - Dr. David Kavtaradze- Site Number : 8400017
Cordele, Georgia · Recruiting
University of Kansas Medical Center- Site Number : 8400005
Kansas City, Kansas · Recruiting
Johns Hopkins Bayview Medical Center- Site Number : 8400009
Baltimore, Maryland · Recruiting
Brigham & Women's Hospital- Site Number : 8400014
Boston, Massachusetts · Recruiting
American Health Research - Charlotte- Site Number : 8400013
Charlotte, North Carolina · Recruiting
Atrium Health Wake Forest Baptist Pulmonary, Sleep And Allergy- Site Number : 8400004
Winston-Salem, North Carolina · Recruiting
Clinical Research Associates of Central Pennsylvania- Site Number : 8400002
DuBois, Pennsylvania · Recruiting
REX Clinical Trials - Beaumont- Site Number : 8400011
Beaumont, Texas · Recruiting
Investigational Site Number : 0320002
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320003
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320001
San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting
Investigational Site Number : 0400005
Linz, Austria · Recruiting
Hospital Beneficência Portuguesa de São Paulo- Site Number : 0760006
São Paulo, Brazil · Recruiting
Incor - Instituto do Coracao- Site Number : 0760001
São Paulo, Brazil · Recruiting
Hospital Dom Pedro De Alcantara- Site Number : 0760009
Feira de Santana, Estado de Bahia, Brazil · Recruiting
Associacao Proar- Site Number : 0760005
Salvador, Estado de Bahia, Brazil · Recruiting
Clínica CLARE- Site Number : 0760004
Goiânia, Goiás, Brazil · Recruiting
Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760002
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Investigational Site Number : 1240005
Calgary, Alberta, Canada · Recruiting
Investigational Site Number : 1240002
London, Ontario, Canada · Recruiting
Investigational Site Number : 1560005
Chengdu, China · Recruiting
Investigational Site Number : 1560013
Guangzhou, China · Recruiting
Investigational Site Number : 1560001
Guangzhou, China · Recruiting
Investigational Site Number : 1560004
Hangzhou, China · Recruiting
Investigational Site Number : 1560010
Harbin, China · Recruiting
Investigational Site Number : 1560012
Ningbo, China · Recruiting
Investigational Site Number : 1560009
Xiamen, China · Recruiting
Investigational Site Number : 2080003
Aalborg, Denmark · Recruiting
Investigational Site Number : 2080002
Vejle, Denmark · Recruiting
Investigational Site Number : 2500008
La Tronche, France · Recruiting
Investigational Site Number : 2500001
Lille, France · Recruiting
Investigational Site Number : 2500005
Lyon, France · Recruiting
Investigational Site Number : 2500006
Marseille, France · Recruiting
Investigational Site Number : 2500002
Montpellier, France · Recruiting
Investigational Site Number : 2500003
Pessac, France · Recruiting
Investigational Site Number : 2500004
Reims, France · Recruiting
Investigational Site Number : 2760003
Berlin, Germany · Recruiting
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.